MiNK Therapeutics Third Quarter 2026 Financial Results - MINK THERAPEUTICS INC

Explicit Guidance:

• U.S. clinical dosing for the Phase II ARDS trial expected to commence before year-end 2026.
• Comparative data readout for the randomized ARDS Phase II study anticipated in 2027 (specifically targeting Q3 2027 for the initial randomized stage readout).
• Colorectal cancer study data readout expected early in 2027.
• First patient dosing for the Phase I GVHD prevention study scheduled for the second half of 2026 (adjusted from first-half guidance).
• Net loss per share guidance is implicitly negative but decreasing trajectory is emphasized; specific dollar amounts or EPS ranges for future quarters are not provided.
• ARPA-H BOSS program funding: Up to $87 million committed over a four-year period (fixed fee basis).

Business-Segment Outlook:

• Acute Lung Injury/ARDS: Expanded target population to 93,000 U.S. patients annually (ventilated, pneumonia-associated, moderate-severe ARDS); study design may adapt to a seamless Phase 2B/3 with enrollment expanding from 124 to 300 patients.
• Oncology: Phase 2 study at Scripps (MSS colorectal cancer with liver mets) actively enrolling; strategy to combine Agent 797 with BOT and BAL to unlock tumor killing.
• Fibrosis/Senolytics: Leveraging "living senolytic" capabilities of Agent 797 and MINK215 to target fibrosis in lung disease and cancer; potential to transition from acute ICU use to chronic interstitial lung disease (ILD) clinics.
• Named Patient Program: Currently active in multiple countries outside the U.S. (started August); revenue expected to be variable quarter-to-quarter based on regulatory authorization; intends to expand into additional markets where regulations permit.

Market and Competitive Outlook:

• Competitive Landscape: FDA providing clearer target population definitions for ARDS; no currently approved effective therapies for ARDS; growing strategic interest in the space (e.g., ADESA-QR licensing deal) due to unmet need and high mortality (~40-50%).
• Differentiation: Agent 797 offers off-the-shelf delivery (no apheresis/HLA matching), rapid anti-inflammatory signature (48-72 hours), pathogen clearance, and potential to prevent progression to chronic fibrosis, distinguishing it from current supportive care and single-mechanism competitors.
• Market Expansion: Potential to extend beyond critical care into chronic ILD, senescence-related aging, and broader cancer indications via engineered INKT medicines.

Macro / Industry Outlook:

• Post-COVID Impact: Recognition of persistent hyper-inflammatory phenotypes and long-term pulmonary disability/fibrosis in 1/3 of ARDS patients (including non-COVID) five years post-pandemic, driving urgency for therapies that mitigate acute inflammation and prevent chronic sequelae.
• Regulatory Environment: FDA alignment sought to support hierarchical endpoints (survival without ECMO at day 14 + mortality at day 28) and potential contribution of Phase 2 patients to Phase 3 registration cohorts.

Strategic Initiatives:

• ARPA-H BOSS Program: Selected as therapeutic cell system to develop room-temperature storage for allogeneic cell therapies; aims to remove cryogenic barriers to enable stockpiling in community hospitals.
• Trial Design: Pursuing FDA alignment for adaptive Phase 2B/3 seamless design to accelerate registration pathway; plans to refine study endpoints based on biomarker stratification.
• Capacity & Supply: Validated ability to supply inventory across borders (cryopreserved cells) to support simultaneous clinical trials and named patient access.
• Funding Strategy: Prioritizing non-dilutive funding (ARPA-H, NIAID STTR, Mary Guth Award, C-FURTHER partnership) to support randomized studies through readout; seeking additional equity/debt to strengthen balance sheet.

Risks and Headwinds to Outlook:

• Enrollment & Timeline: U.S. site activation is in final stages (risk of delay); U.S. dosing timing depends on site selection and regulatory approvals.
• Regulatory Uncertainty: FDA alignment on hierarchical endpoints and seamless study design is required; failure to agree could alter the development path.
• Data Interpretation: Early observations are from small, non-comparator cohorts; randomized evidence is required to validate efficacy and safety.
• Operational Complexity: Managing cross-border logistics for named patient access and ensuring standardized of care in Ukrainian sites (Lviv) vs. U.S. sites.
• Financial: Cash position ($7.5M at quarter end) requires continued funding to sustain operations until next readout; net loss persists.

Management Tone on the Future:

• Confidence: High confidence in the biology ("cells read the disease") and early clinical signals (70-75% survival vs. 40% historical mortality); describing the data as "validating" Phase 1-2 observations.
• Urgency: Emphasis on "rapid development pathway" and "immediate window" for treatment (first few days of critical illness).
• Strategic Clarity: Deliberately focused on randomized evidence and regulatory execution; management tone suggests a shift from discovery to execution and validation.

Miscellaneous:

• Biomarkers: Developing predictive biomarker sets to identify patients most likely to respond; will be a key discussion point with FDA for patient stratification.
• Fibrosis Link: Strong scientific rationale connecting acute ARDS recovery to prevention of long-term fibrosis (idiopathic pulmonary fibrosis) via clearance of senescent cells.